Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$6.1MCash on Hand
9.4mo Cash Runway
Follow PPBT by emailGet an email when PPBT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PPBT, unsubscribe in one click. Privacy
📣 What PPBT Says Is Next
in 2026 · “These findings support our development roadmap as we prepare for anticipated key milestones in 2026 and advance CAPTN-3 toward IND-enabling studies.” “The NKG2A/HLA-E axis is emerging as a key post-treatment resistance mechanism, as previously shown by Dr. Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai,” said Dr. Hadas Reuveni, VP Research and Development at Purple Biotech.”
Company press release, Dec 11, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Earnings Purple Biotech reported Q3 2026 net loss of $1.0 million, down from $1.3 million, with $5.1 million in cash and equivalents expected to fund operations through late 2027. IM1240 abstract selected for a plenary oral presentation on November 20, 2026, and a U.S. Form 6-K · SEC filing · Press release
Oct 5, 2026 ·
Leadership Purple Biotech appointed director Isaac Israel, its former CEO, as Interim Chief Executive Officer effective October 5, 2026, pending a permanent CEO. Gil Efron steps down as CEO and becomes Executive Director, Head of Corporate Development, and remains on the Board. Form 6-K · SEC filing
Sep 9, 2026 ·
Shareholder vote Purple Biotech held its Annual General Meeting of Shareholders on September 8, 2026, and reported that each proposal in the Proxy Statement was approved by the requisite vote under Israeli law and its articles of association. Form 6-K · SEC filing
Sep 2, 2026 ·
Purple Biotech reported a U.S. Notice of Allowance from the USPTO for a patent application on tri-specific antibody constructs supporting its CAPTN-3 modular platform. The company says the allowance strengthens protection for the platform, subject to payment of issue fees. Form 6-K · SEC filing · Press release
Aug 10, 2026 ·
Purple Biotech issued an updated corporate presentation dated August 2026, attached as Exhibit 99.1. It reports $6.1M cash as of June 30, 2026, runway into mid 2027, and a lead program, IM1240, expected to enter the clinic in 2027. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PPBT holds $6.1M in cash and short-term investments and burns about $1.9M/quarter from operations,
an estimated runway of 9.4 months at that rate (BioRadar estimate, not company guidance).
Share count 1,858,911,801 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PPBT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PPBT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.